Stallergenes Greer plc Result of AGM
June 07 2018 - 11:30AM
UK Regulatory
TIDM0RB9
The shareholders of Stallergenes Greer plc (Paris:STAGR), a
biopharmaceutical company specialising in treatments for
respiratory allergies, announces that all resolutions proposed by
the Board of Directors at the company's Annual General Meeting
(AGM) were duly passed today. All resolutions were set out in the
Notice of Meeting posted to shareholders on 23 April 2017.
Notably, shareholders re-elected Chairman and CEO Fereydoun
Firouz, and Directors, Jean-Luc BĂ©lingard, Rodolfo Bogni, Stefan
Meister, Yvonne Schlaeppi and Elmar Schnee - each for a further
term of one year.
The terms of Patrick Langlois and Paolo Ricci have expired at
the end of the AGM. The Board would like to thank both Patrick for
his contributions to Stallergenes Greer as a Board member and Chair
of the Audit Committee, and Paola for her contributions as a Board
member.
In addition, Philip Broadley was elected as a Director with a
one-year term. Mr Broadley has significant financial and
international business experience, having previously been Group
Finance Director of Prudential plc for eight years and Old Mutual
plc for six years. He is currently a director of AstraZeneca plc
and serves on their Audit Committee, and is also a director and the
Audit Committee chairman of Legal & General Group plc. He is a
member of the Oxford University Audit Committee, Treasurer of the
London Library and Chairman of Governors at Eastbourne College. He
is a Fellow of the Institute of Chartered Accountants in England
and Wales. Mr Broadley started his career at Arthur Andersen where
he was a partner for seven years. He is a past Chairman of the 100
Group of Finance Directors in the UK and served as a member of the
Code Committee of the Takeover Panel. He graduated in Philosophy,
Politics and Economics from St Edmund Hall, Oxford and has an MSc
in Behavioural Science from the London School of Economics.
"2017 continued a transformation at Stallergenes Greer to
improve our operations, serve our customers and deliver a strong
performance. I would like to thank all of our Directors for their
contributions and guidance, and our shareholders for their
continued support. I would also like to welcome Philip Broadley to
our Board of Directors. Philip has extensive experience in
corporate finance and will be a valuable contribution to our Board
and Audit Committee where he will serve as Chair," said Chairman
and CEO, Fereydoun Firouz, "We remain focused and committed to
strengthening our leadership position, driving excellence across
our business and positioning our company for long-term growth in
order to deliver value to our shareholders, customers and
employees."
The full text of each resolution is set out in the Notice of
Annual General Meeting, which is available on Stallergenes Greer's
website at www.stallergenesgreer.com.
ABOUT STALLERGENES GREER PLCHeadquartered in London (UK),
Stallergenes Greer plc is a global healthcare company specializing
in the diagnosis and treatment of allergies through the development
and commercialization of allergy immunotherapy products and
services. Stallergenes Greer plc is the parent company of GREER
Laboratories, Inc. (whose registered office is in the US) and
Stallergenes SAS (whose registered office is in France).
TRADING INFORMATIONName: Stallergenes GreerISIN: GB00BZ21RF93 1
- Ticker: STAGRICB Classification: 4577LEI:
213800CYVZA7GJQEME86Market: Euronext Paris regulated market
Additional information is available at
http://www.stallergenesgreer.com.
This document (including information incorporated by reference
in this document), oral statements made and other information
published by the Company contain statements that are or may be
forward-looking with respect to the financial condition and/or
results of operations and businesses of the Company. These
statements can be identified by the use of forward-looking
terminology such as "believe," "expects," "project," "estimated,"
"forecast," "should," "plan," "may" or the negative of any of
these, or other variations thereof, or comparable terminology
indicating expectations or beliefs concerning future events. These
forward-looking statements include risk and uncertainty because
they relate to events and depend on circumstances that will occur
in the future. Without being exhaustive, such factors include
economic situations and business conditions, including legal and
product evaluation issues, fluctuations in currencies and demand,
and changes in competitive factors. These and other factors are
more fully described in the Company's 2016 annual report published
on 16 April 2018 on the Company's website
www.stallergenesgreer.com. Actual results may differ from those set
forth in the forward-looking statements, due to various factors.
Save as required by applicable law, neither the Company nor any
other person assumes any obligation to update these forward-looking
statements or to notify any person of any such update.
Communications and Investor RelationsStallergenes Greer
plcNatacha Gassenbach, Tel: +1 (617) 682 2626Email:
natacha.gassenbach@stallergenesgreer.comCaitlin Stefanik, Tel: +1
(857) 331 4117Email: caitlin.stefanik@stallergenesgreer.comorMedia
Relations AgencyHavas Paris (Europe)Samuel Rousseau, +33 6 77 88 32
43E-mail : samuel.rousseau@havas.comorInvestor Relations AgencyFTI
ConsultingArnaud de Cheffontaines, Tel: +33 1 47 03 68 10Email:
stalleregenesgreer@fticonsulting.com
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180607005624/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
June 07, 2018 12:30 ET (16:30 GMT)
Stallergenes Greer (LSE:0RB9)
Historical Stock Chart
From Apr 2024 to May 2024
Stallergenes Greer (LSE:0RB9)
Historical Stock Chart
From May 2023 to May 2024